EVAMPLIX
Dead / Abandoned — Abandoned — no statement of use filed (as of 16 Jun 2025)
What this means for you
This application is over — abandoned 16 Jun 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97652406
- Mark type
- Stylized text
- Filed
- 28 Oct 2022
- Published for opposition
- 19 Sept 2023
- Abandoned
- 16 Jun 2025
- Attorney of record
- Christina M. Licursi
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical, therapeutic and biopharmaceutical agents for the treatment of cancer, infectious diseases, autoimmune disorders, transplant rejections, and inflammatory diseases; pharmaceutical, therapeutic and biopharmaceutical preparations and substances for the treatment of cancer, infectious diseases, autoimmune disorders, transplant rejections, and inflammatory diseases; biological preparations, namely, antibodies for the treatment of cancer, infectious diseases, autoimmune disorders, transplant rejections, and inflammatory diseases
Owner
- Agenus Inc., Lexington, MA, US
- Agenus Inc., Lexington, MA, US
Prosecution history
- 16 Jun 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 16 Jun 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 03 Jan 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Jan 2025 — SOU EXTENSION 2 GRANTED
- 13 Nov 2024 — SOU EXTENSION 2 FILED
- 30 Dec 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 13 Nov 2024 — SOU TEAS EXTENSION RECEIVED
- 15 May 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 May 2024 — SOU EXTENSION 1 GRANTED
- 14 May 2024 — SOU EXTENSION 1 FILED
- 14 May 2024 — SOU TEAS EXTENSION RECEIVED
- 14 Nov 2023 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 19 Sept 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 19 Sept 2023 — PUBLISHED FOR OPPOSITION
- 30 Aug 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED